🔗 Share this article

As the United States continues making historic revisions to its vaccination guidelines, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by questioning Covid vaccines during the global health crisis and has focused upon possible deaths after Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Proposed Overhauls to Childhood Immunization Program

Health officials planned to reveal radical changes to the childhood vaccine schedule recently, aligning the US with the Danish immunization schedule, according to reports – a significant shift that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to present at the meeting. She was recently named interim head of the FDA’s CDER, the fifth individual to head the center this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Prasad solidify control at the agency – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

The new acting director has frequently advocated for halting certain childhood shot schedules in the US so as to align more in line with the Danish model, a nation with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has no apparent background in drug development, regulation or leadership, which has been customary for previous directors of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the CDER, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a major agency. She has no expertise in drug approvals.”

Previous directors of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, commented a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that previous people who ran CBER have had.”

CDER has an immense workload at the FDA, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the generic drug division clears numerous generic drugs. There is also a biosimilars division, over-the-counter program and more, and every single one must be looked after,” Woodcock said. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a substantial management component to the position, which manages more than 5,000 staff members. “It is a enormous administrative position, if you do it right,” Woodcock concluded.

Response and Disputed Programs

In response to concerns about Høeg’s qualifications and whether this assignment indicates increased cooperation among agency officials on vaccines, a press secretary stated that the “questions rely on inaccurate premises”.

“Her resume is consistent with the functions of her role,” the representative said, citing the months Dr. Høeg spent counseling the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched priority voucher program, a controversial expedited drug-approval program that reportedly concerned her predecessors. “By what process are these medications being selected for this voucher program? Who makes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, aside from vaccines.”

Established History on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, past, critics have noted. She released a study using non-validated volunteer-provided data to estimate the incidence of heart inflammation following Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the current federal leadership encompassed altering guidelines for recently developed shots and discontinuing “optional” vaccines, she remarked post-election on a online show. At the FDA, Dr. Høeg has reportedly proposed preventing young men from getting Covid vaccinations.

“She’s an all-around ideologue who starts off with her conclusions and works backwards to retrofit the data in a very misleading, untruthful manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Høeg aligned with fellow skeptics, {like|